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Abstract
Background: The aim of this study was to assess the effects of darapladib, a selective oral investigational lipoprotein-
associated phospholipase A2 inhibitor, on both plasma and plaque lipoprotein-associated phospholipase A2 activity.
Methods: Patients undergoing elective carotid endarterectomy were randomized to darapladib 40 mg (n = 34), 80 mg
(n = 34), or placebo (n = 34) for 14 days, followed by carotid endarterectomy 24 hours after the last dose of study
medication.
Results: Darapladib 40 mg and 80 mg reduced plasma lipoprotein-associated phospholipase A2 activity by 52% and 81%,
respectively, versus placebo (both P,0.001). Significant reductions in plaque lipoprotein-associated phospholipase A2
activity were also observed compared with placebo (P,0.0001), which equated to a 52% and 80% decrease compared with
placebo. No significant differences were observed between groups in plaque lysophosphatidylcholine content or other
biomarkers, although a dose-dependent decrease in plaque matrix metalloproteinase-9 mRNA expression was observed
with darapladib 80 mg (P= 0.053 vs placebo). In a post-hoc analysis, plaque caspase-3 (P,0.001) and caspase-8 (P,0.05)
activity were found to be significantly lower in the darapladib 80-mg group versus placebo. No major safety concerns were
identified in the study.
Conclusions: Short-term treatment (1464 days) with darapladib produced a robust, dose-dependent reduction in plasma
lipoprotein-associated phospholipase A2 activity. More importantly, darapladib demonstrated placebo-corrected reductions
in carotid plaque lipoprotein-associated phospholipase A2 activity of similar magnitude. Darapladib was generally well
tolerated and no safety concerns were identified. Additional studies of longer duration are needed to explore whether these
pharmacodynamic effects are associated with improved clinical outcomes, as might be hypothesized.
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Introduction
Despite medical and scientific advances over the past 15 years,
the burden associated with atherosclerotic cardiovascular (CV)
disease remains unacceptably high. Broadening treatment
targets to include lipid-related risk factors beyond currently
recognized CV risk markers may help further improve clinical
outcomes [1]. Additional processes within the vessel wall,
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particularly inflammatory responses, contribute to plaque desta-
bilization, atherothrombosis, and the clinical sequelae. Mediators
of these processes therefore represent potential novel treatment
targets for reducing CV risk and the burden associated with
atherosclerotic CV disease.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an
emerging CV risk marker that may play an important pathoge-
netic role in mediating inflammatory processes that contribute to
plaque vulnerability and rupture [2]. Although Lp-PLA2 has been
described as a platelet-activating factor (PAF) acetylhydrolase [3],
accumulating evidence suggests that the products of Lp-PLA2,
lysophosphatidylcholine (lysoPC) and oxidized nonesterified fatty
acids, can elicit a broad range of proinflammatory and pro-
apoptotic effects [4]. Lp-PLA2 is produced and secreted by
activated macrophages and other inflammatory cells implicated as
playing a central role in atherothrombosis [5]. More recently, it
has been shown that the so-called proinflammatory macrophage
(M1 phenotype) expresses and secretes greater quantities of Lp-
PLA2 when compared with M2 polarized macrophages [6]. Since
M1 inflammatory macrophages tend to be located within the lipid
core of vulnerable plaques [7], the association described above
presumably explains why Lp-PLA2 is highly upregulated in
macrophages located within the necrotic core and fibrous cap of
vulnerable and ruptured human coronary plaques, but not within
stable lesions [8]. Indeed, in patients who underwent carotid
endarterectomy, levels of Lp-PLA2 and one of its products,
lysoPC, were higher in plaques from patients who had experienced
CV events compared with those who had not, suggesting that Lp-
PLA2 was a key component of a causal pathway for plaque
vulnerability [9–11]. A recent analysis of carotid plaque Lp-PLA2
and lysoPC content demonstrated a highly statistically significant
correlation of both biomarkers with various plaque M1 macro-
phage-related proinflammatory cytokines such as IL-6, tumor
necrosis factor-a and monocyte chemoattractant protein-1 [11].
Finally, a pro-atherothrombotic role for Lp-PLA2 is further
supported by a body of epidemiologic evidence suggesting a
greater risk of CV events with elevated plasma Lp-PLA2 [12].
Darapladib is an oral, investigational, highly potent, and
selective Lp-PLA2 inhibitor that has been demonstrated to reduce
atherosclerosis in a diabetic and hypercholesterolemic porcine
model of accelerated coronary atherosclerosis [13] as well as in
ApoE-deficient mice [14]. Administration of darapladib in the pig
model not only inhibited coronary artery lesion development, but
more profoundly reduced progression to advanced coronary
lesions. A similar observation was noted in the IBIS-2 (Integrated
Biomarker and Imaging Study 2) clinical trial, which compared
the effects of 12 months of darapladib treatment with placebo on
plasma C-reactive protein levels and coronary atheroma compo-
sition and deformability in 330 patients with angiographically
documented coronary artery disease [15]. Although the primary
end points of the study were not met, and darapladib did not affect
total atheroma volume, treatment did halt the increase in necrotic
core volume as assessed by intravascular ultrasound virtual
histology, suggesting a stabilization of the overall plaque. Whether
these changes will translate into differences in clinical outcomes
awaits the results of two large, fully enrolled, ongoing phase III
trials: STABILITY (Stabilization of Atherosclerotic Plaque by
Initiation of Darapladib Therapy Trial, NCT00799903), involving
15,828 patients with coronary heart disease [16], and SOLID-
TIMI 52 (Stabilization of Plaques Using Darapladib - Thrombol-
ysis in Myocardial Infarction 52 Trial, NCT01000727), involving
13,026 subjects with a recent history of acute coronary syndrome
[17].
The primary objective of the current study was to test the
hypothesis that darapladib could reduce the elevated Lp-PLA2
activity within advanced atherosclerotic (carotid) plaques in a
dose-dependent manner. The secondary objectives were more
exploratory in nature, given the very short treatment period, and
focused on changes of several potentially relevant plaque
biomarkers, including an analysis of species of lysoPC. A portion
of the data has been presented in abstract format [18].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
CONSORT Checklist S1.
Patients
Men and women 35 years or older with carotid atherosclerosis
requiring endarterectomy were eligible for participation in this
study. Major exclusion criteria were a history of myocardial
infarction within 4 weeks prior to screening, initiation or alteration
of a lipid-modifying regimen within 4 weeks prior to randomiza-
tion, and a history of unstable angina without evolution of
myocardial infarction (based on electrocardiogram or clinical
laboratory marker criteria), but with transient ST elevation or
depression, or T-wave inversion associated with pain; or in the
absence of electrocardiogram changes, a documented history of
prior myocardial infarction or angiographic coronary artery
stenosis. Patients were recruited from January 27, 2003, until
June 11, 2003, and followed up until July 14, 2003.
Study Design and Conduct
This randomized, double-blind, placebo-controlled, parallel-
group study was conducted in 20 participating study centers
throughout Europe (ClinicalTrials.gov identifier: NCT01916720;
www.clinicaltrials.gov/ct2/show/NCT01916720; GSK trial iden-
tifier: 480848/010; www.gsk-clinicalstudyregister.com/result_
detail.jsp?protocolId = 480848%2F010&studyId = 74F5DB65-
4661-4FA8-91D4-EBF78D769F24&compound = darapladib&type =
Compound&letterrange = A-F). Eligible subjects were randomly
assigned (1:1:1 fashion) to treatment with either darapladib 40 mg
or 80 mg or matching placebo once daily. The randomization was
stratified by statin use and gender. Allocation of eligible subjects
was determined using a computer-generated list of random
numbers. A central randomization schedule was created by the
GSK study statistician using CMS, a GlaxoSmithKline internal
randomization system, with a 1:1:1 allocation ratio between 3
treatment groups, using the block size of 4. The GSK Registration
and Medication Ordering System (RAMOS) was used to
sequentially allocate treatments to subjects as per the randomiza-
tion generated within CMS. RAMOS also provided central
allocation of drug supplies. Study medication was dispensed
according to the protocol to randomized subjects under the
supervision of the investigator: placebo patients received 2 bottles
of placebo (pbo) and took two tablets from each bottle (i.e.,
46pbo); 40 mg patients received 1 bottle of 20 mg tablets and 1
bottle of placebo and took two tablets from each bottle (i.e., 2620
mg+26pbo); 80 mg patients received 2 bottles of 20 mg and took
two tablets from each bottle (i.e., 4620 mg). Subjects, physicians,
and site staff associated with the study, as well as GlaxoSmithKline
teams, were blinded and unaware of the allocated treatment.
The duration of treatment was 1464 days and was planned to
immediately precede elective carotid endarterectomy. The last
dose of study medication was administered on the day prior to the
surgical procedure, which was carried out according to the
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guidelines set forth by the local institution. Data were collected by
the investigators at each site and analyzed by the sponsor.
Ethics Statement
Subjects provided written, informed consent, and the protocol
was approved by each study site’s respective ethics committee:
Ethical Committee of the Hospital District of Helsinki and
Uusimaa, ophthalmology, otorhinolaryngology, neurology and
neurosurgery, Helsinki, Finland; CCPPRB Paris-Pitie`-Salpe´trie`re,
Hoˆpital Pite´-Salpe´trie`re, Pavillon Jacquart, Paris, France; Uni-
versita¨tsklinikum Benjamin-Franklin Ethikkommission, Berlin,
Germany; Otto-von Guericke-Universita¨t Ethikkommission, Mag-
deburg, Germany; Ethikkommission der Westfa¨lischen Wilhelms-
Universita¨t Mu¨nster, Mu¨nster, Germany; Landesa¨rztekammer
Hessen Ethikkommission, Frankfurt, Germany; Medisch Ethische
Toetsingscommissie UMC Utrecht, Utrecht, Netherlands; Sint
Antonius Ziekenhuis TME, Nieuwegein, Netherlands; Komisja
Bioetyczna CMKP, Warsaw, Poland; Comite´ Etico de Investiga-
cio´n Clı´nica, H. Clı´nico de Barcelona, Barcelona, Spain;
SERGAS, Comite´ Etico de Investigacio´n Clı´nica, Santiago de
Compostela, Spain; Comite´ Etico de Investigacio´n Clı´nica,
Servicio Farmacologı´a Clı´nica, H. San Creu y San Pau,
Barcelona, Spain; Comite´ Etico de Investigacio´n Clı´nica, H de
Bellvitge, Barcelona, Spain; Comite´ Etico de Investigacio´n
Clı´nica, H Central de Asturias, Oviedo, Spain; Comite´ Etico de
Investigacio´n Clı´nica, H. Vall d.Hebro´n, Barcelona, Spain; United
Bristol Healthcare Trust Ethics Committee, UBHT Headquarters,
Bristol, UK; East Dorset Local Research Ethics Committee, Poole
Hospital NHS Trust, Poole, UK; Bath Local Research Ethics
Committee, Royal United Hospital, Bath, UK. This study was
conducted in accordance with Good Clinical Practice Guidelines
and guiding principles of the Declaration of Helsinki.
Measurements
The excised plaque was rinsed in saline, frozen in liquid
nitrogen, transferred to a 50 mL Falcon tube, and stored at 2
70uC or in liquid nitrogen. Specimens were shipped using dry ice
transport to Quest Diagnostics Clinical Trials (Heston, Middlesex,
United Kingdom) for storage. Plaque samples were shipped to
GlaxoSmithKline for analysis of Lp-PLA2 activity (Human
Biomarker Centre, Ware, Hertfordshire, United Kingdom),
phospholipids (Human Biomarker Centre/University of South-
ampton), and biomarker gene expression (CD68, CD3, a-actin,
CD40 ligand [CD40L], matrix metalloproteinase [MMP]-2,
MMP-9, plasminogen activator inhibitor [PAI]-1, intercellular
adhesion molecule [ICAM]-1, interleukin [IL]-6, and Lp-PLA2;
Quantitative Expression and Genomic Histology Department,
Stevenage, Hertfordshire, United Kingdom). Lp-PLA2 activity and
lysoPCs were assessed in excised lesions as previously described
[13] and included lysoPC 16:1, lysoPC 16:0, lysoPC 18:2, lysoPC
18:1, lysoPC 18:0, lysoPC 20:4, lysoPC 20:3, and lysoPC 22:6.
The expression of biomarkers was captured as the cDNA copy
numbers from TaqManTM (Applied Biosystems, Inc., Foster City,
California, USA) real-time polymerase chain reaction analyses.
Blood samples were obtained immediately prior to the first dose
(i.e., baseline) and again after 1464 days of treatment with study
medication. Blood samples were centrifuged at 4uC, frozen at -
70uC, and shipped to Quest Diagnostics Clinical Trials (using dry
ice transport) for storage. Clinical laboratory chemistries and
plasma biomarker protein concentrations (high-sensitivity C-
reactive protein, CD40L, sICAM-1, E-selectin, PAI-1, and
MMP-9) were assessed at Quest, whereas frozen plasma samples
were shipped to GlaxoSmithKline (Human Biomarker Center,
Philadelphia, Pennsylvania, USA) for analysis of plasma Lp-PLA2
activity. Lp-PLA2 activity in plaque and plasma samples was
measured using a radiometric assay described previously, with
[3H]-PAF as a substrate [19] and normalized to protein content
for plaque measurements.
Based on findings suggesting that products of Lp-PLA2 activity
could promote macrophage apoptosis [20], a post-hoc analysis was
performed using stored plaque specimens to assess the effect of
treatment with darapladib on markers of apoptosis, plaque caspase
activity (effector/executioner caspase-3 and initiator caspase-8).
Stored specimens were available only from a subset of patients
from the study (for caspase-3, n = 23, n = 21, and n = 15 for the
placebo, 40-mg, and 80-mg groups, respectively; for caspase-8,
n = 10, n = 17, and n = 10, respectively). Colorimetric assays
(BioVision, Mountain View, California, USA) were used to
measure caspase-3 and caspase-8 activity, with DEVD-pNA and
IETD-pNA as the substrates, respectively, and the values are
presented as geometric mean (6SEM) activity units per milligram
of protein (AU/mg).
Safety assessments included clinical laboratory chemistries on
blood samples obtained at baseline, on Day 7 (62), on Day 15,
and 28 (67) days following the last dose of study medication.
Physical examinations (during which vital signs were obtained)
were performed at these same points during the trial. An
electrocardiogram was obtained at baseline, on Day 15, and 28
(67) days following the last dose of study medication.
Statistical Analyses
The primary end point measure of the study was Lp-PLA2
activity within the atherosclerotic plaque removed during carotid
endarterectomy following 14 (64) days of treatment with
darapladib, adjusted by sex and statin use. Sample size calculations
indicated that 33 enrolled subjects would be needed for each
treatment group to achieve 27 evaluable subjects to detect a 50%
difference in plaque Lp-PLA2 activity between darapladib (either
dose) and placebo (with a standard deviation of 0.7 on a log-
transformed scale), with 90% power. Secondary efficacy end
points included the percent inhibition of Lp-PLA2 activity in
blood, and the concentration and/or mRNA expression of other
biomarkers.
A Bonferroni adjustment was used for primary efficacy analyses
to allow for a comparison of each darapladib dose to placebo, with
a 2.5% significance level for each comparison with placebo
(maintaining an overall 5% significance level for the primary end
point). The log-transformed Lp-PLA2 activity was analyzed using
parametric analysis of covariance (including terms for sex and
statin use), and the differences between treatment groups versus
placebo in the primary efficacy end point were presented as mean
values with 97.5% confidence intervals (CI).
Results
One hundred and three eligible subjects were randomly
assigned to a treatment group; the disposition of these participants
is summarized in Figure 1. One subject assigned to darapladib
40 mg did not receive any study medication because of a protocol
deviation (history of asthma). Safety assessments were performed
on the remaining 102 subjects (n = 34 per treatment group) who
received at least 1 dose of study medication. Overall, 98 (96.1%)
subjects completed the study. One subject in the darapladib 80-mg
group withdrew from the study prematurely because of an adverse
event; this subject experienced a hypertensive crisis while receiving
anesthesia in preparation for carotid endarterectomy, 1 day
following the completion of study medication. One subject in the
placebo group withdrew from the study because the carotid
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endarterectomy was not performed within 1 day of the last dose of
study medication. Two subjects (1 in the darapladib 40-mg group
and 1 in the placebo group) withdrew because surgery was not
performed due to severe coronary artery disease. The primary
efficacy analyses were performed on data from 89 of 103 (86.4%)
participants (n = 30 in the placebo group, n = 30 in the darapladib
40-mg group, and n = 29 in the darapladib 80-mg group) who
received at least 1 dose of study medication and had evaluable Lp-
PLA2 activity data from their excised plaques.
Demographic characteristics of the study population at baseline
are summarized in Table 1. The mean degree of carotid artery
stenosis in the study population is consistent with guideline
recommendations for endarterectomy. At 24 hours following the
last dose of study medication, Lp-PLA2 activity in the excised
plaque was approximately 52% (97.5% CI, 228% to 268%)
lower in the darapladib 40-mg group compared with the placebo
group (treatment difference =20.737 nmol of PAF/min/mg of
total protein [97.5% CI, 21.15 nmol/min/mg to 20.32 nmol/
min/mg], P,0.001). The adjusted mean difference in plaque Lp-
PLA2 activity between the darapladib 80-mg group and the
placebo group was 21.60 nmol of PAF/min/mg of total protein
(97.5% CI, 22.02 nmol/min/mg to 21.19 nmol/min/mg, P,
0.001), which equates to an approximately 80% (97.5% CI,269%
to 287%) reduction in plaque Lp-PLA2 activity. The placebo-
corrected reduction in plasma Lp-PLA2 activity 24 hours following
the last dose of study medication was comparable to that observed
in plaque (Figure 2). Respectively, treatment with darapladib
40 mg and 80 mg resulted in a 52% (95% CI, 244% to 260%)
and an 81% (95% CI, 273% to 289%) reduction in adjusted
mean plasma Lp-PLA2 activity versus placebo. Consistent with
prior studies, there was a significant correlation between baseline
plasma Lp-PLA2 activity and baseline fasting cholesterol levels
(Spearman correlation 0.48, P,0.001).
No statistically significant differences were observed between
treatment groups in the lysoPC content in plaques (Figure 3). The
mean plaque concentration of lysoPC (total) at the end of study
treatment in the placebo, darapladib 40-mg, and darapladib 80-
mg groups was 3.65 (61.63) mmol/g of tissue, 3.39 (62.05) mmol/
g of tissue, and 3.14 (61.49) mmol/g of tissue, respectively
(P= NS). Likewise, no significant differences were observed for the
predominant lysoPC species that are known products of Lp-PLA2
activity, namely, LPC16:0, LPC18:0, and LPC18:1 (Figure 3) [21].
No statistically significant differences were observed between the
treatment arms for other plasma biomarkers; however, with
respect to plaque biomarkers, treatment with darapladib 80 mg
produced a,33% reduction in the geometric mean plaque MMP-
9 mRNA expression compared with placebo that appeared to be
dose dependent. The difference between groups was not statisti-
cally significant for this (P= 0.053 vs placebo, based on absolute
differences) or any of the other prespecified biomarkers (Figure 4).
The effects of darapladib on caspase-3 and caspase-8 activity
from stored samples are shown in Figure 5. Based on this post-hoc
analysis, the activity of both caspases was significantly lower
among those receiving darapladib 80 mg compared with placebo
(P,0.001 for caspase-3 and P,0.05 for caspase-8). Using
Spearman’s rank method, statistically significant correlations were
observed between plasma Lp-PLA2 activity and plaque caspase-3
activity (r = 0.51, P,0.0001) and between plasma Lp-PLA2
activity and plaque caspase-8 activity (r = 0.34, P= 0.039).
Treatment with darapladib in this study was generally well
tolerated; no clinically meaningful differences were observed
between the placebo group and each darapladib group in vital
signs, electrocardiograms, or clinical laboratory parameters. The
most common adverse events reported during treatment and the
post-treatment follow-up period are summarized in Table 2. The
most common adverse events with a probable relationship to study
medication during the treatment phase were dysgeusia and fecal
malodor; however, no subjects withdrew as a result of these events.
As mentioned previously, one subject in the darapladib 80-mg
group withdrew from the study prematurely because of an adverse
event (hypertensive crisis while receiving anesthesia in preparation
for carotid endarterectomy); however, this event was considered to
be unrelated to the study medication.
The majority of adverse events reported during treatment were
rated as mild or moderate in intensity. Five subjects, 3 in the
darapladib 40-mg group and 2 in the darapladib 80-mg group,
experienced a serious adverse event; however, none of these
serious adverse events was considered to be related to study
treatment.
Discussion
This study demonstrated that short-term (14 days 64 days)
treatment with darapladib, a novel, selective Lp-PLA2 inhibitor,
consistently produced a dose-dependent reduction in plasma Lp-
PLA2 activity in patients with carotid artery disease. These data
Figure 1. Disposition of patients throughout the carotid endarterectomy study.
doi:10.1371/journal.pone.0089034.g001
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Table 1. Summary of demographic characteristics in the carotid endarterectomy study.
Placebo Darapladib 40 mg Darapladib 80 mg
(N=34) (N=34) (N=34)
Age, y (mean 6 SD) 66.969.0 66.167.42 64.3612.3
Male, n (%) 28 (82.4) 26 (76.5) 25 (73.5)
BMI, kg/m2 (mean 6 SD) 27.363.12 26.663.75 26.563.58
Caucasian, n (%) 34 (100.0) 34 (100.0) 34 (100.0)
Smoking status, n (%)
Previous 18 (52.9) 16 (47.1) 19 (55.9)
Current 8 (23.5) 11 (32.4) 7 (20.6)
Never 8 (23.5) 7 (20.6) 8 (23.5)
Diabetic, n (%) 10 (29.4) 11 (32.4) 6 (17.6)
Current cardiovascular conditions, n (%)
Carotid artery disease 34 (100) 34 (100) 34 (100)
Cerebrovascular disease 34 (100) 34 (100) 34 (100)
Hypertension 20 (58.8) 20 (58.8) 21 (61.8)
Stroke 3 (8.8) 8 (23.5) 9 (26.5)
Coronary artery disease 9 (26.5) 6 (17.6) 3 (8.8)
TIA 5 (14.7) 6 (17.6) 6 (17.6)
Stable angina 7 (20.6) 4 (11.8) 2 (5.9)
Statin use, n (%) 17 (50.0) 17 (50.0) 19 (55.9)
Degree of carotid artery stenosis, % (mean 6 SD) 83.8610.1 83.4612.2 83.4610.0
Baseline plasma Lp-PLA2 activity*, nmol/min/mL (mean 6 SD) 144.1633.6 133.5630.9 134.2630.1
Baseline total cholesterol level, mmol/L (mean 6 SD) 5.3361.10 4.9560.84 5.3061.17
BMI = body mass index; TIA = transient ischemic attack.
*Data available from n= 29 subjects in each group.
doi:10.1371/journal.pone.0089034.t001
Figure 2. Effect of darapladib treatment (14±4 days) on plaque and plasma lipoprotein-associated phospholipase A2 activity.
Vertical bars for plaque and plasma data points represent 97.5% and 95% confidence intervals (CI), respectively. Baseline plasma Lp-PLA2 activity
levels are provided in Table 1. At Day 15, plasma Lp-PLA2 activity levels (mean 6 SD) for placebo, 40 mg darapladib, and 80 mg darapladib were
141.4639.3, 63.4628.3, and 27.0611.4 nmol/min/ml, respectively. At Day 15, plaque Lp-PLA2 activity levels (mean 6 SEM) for placebo, 40 mg
darapladib, and 80 mg darapladib were 0.9460.14, 0.2660.13, and 0.1160.14 nmol/min/mg protein, respectively.
doi:10.1371/journal.pone.0089034.g002
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are consistent with several other published studies [15,22].
However, this current study is the first to demonstrate that Lp-
PLA2 activity within advanced human atherosclerotic lesions can
be reduced (to a comparable extent as in plasma) following 14 days
of treatment with darapladib. Darapladib was generally well
tolerated in these studies, with no evidence of safety concerns.
Based on the demographic characteristics (mean age, body
weight, medical history, and concomitant medication use) of the
enrolled participants in this study, most patients had documented
carotid disease. The degree of carotid artery stenosis (83.5%) in
this carotid endarterectomy study suggests the presence of
advanced atherosclerotic lesions. Nevertheless, these results
indicate that darapladib distributed into lesions to produce its
pharmacodynamic effect in a dose-dependent manner, with the
40-mg dose associated with a greater than 50% reduction in Lp-
PLA2 activity and the 80-mg dose associated with an 80%
reduction in activity compared with placebo. This demonstration
of a pharmacodynamic effect of darapladib within atherosclerotic
lesions is an important step in exploring whether Lp-PLA2
activity contributes directly to plaque destabilization and
Figure 3. Analysis of plaque lysophosphatidylcholine (lysoPC) content following treatment (14±4 days) with darapladib. Data
represent mean 6 standard deviation.
doi:10.1371/journal.pone.0089034.g003
Figure 4. The influence of darapladib treatment (14±4 days) on the expression (mRNA) of several plaque biomarkers. Vertical bars
represent 95% confidence intervals (CI). CD40L, CD40 ligand; MMP, matrix metalloproteinase; PAI, plasminogen activator inhibitor; ICAM, intercellular
adhesion molecule; IL, interleukin; Lp-PLA, lipoprotein-associated phospholipase A2.
doi:10.1371/journal.pone.0089034.g004
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e89034
Effect of Darapladib on Carotid Plaque Lp-PLA?
atherothrombosis and whether darapladib can modulate these
processes to stabilize plaques and reduce CV risk. It is noteworthy
that a similar level of plaque Lp-PLA2 activity inhibition was
achieved with darapladib in a porcine model of coronary
atherosclerosis, because in this model, Lp-PLA2 inhibition was
accompanied by a significant reduction in complex plaque
development [13]. Also noted in the porcine study with darapladib
treatment was a 72% reduction in the coronary expression of
MMP-9, which is in line with the dose-dependent decrease in
MMP-9 mRNA observed in the current study and may suggest
that plaque MMP-9 expression is downstream of Lp-PLA2 action.
This is of potential significance because MMP-9 is greatly
upregulated in culprit lesions and has been implicated in necrotic
core expansion and plaque vulnerability [23–24].
Results from recent studies indicate that Lp-PLA2 staining/
expression is most intense in lesions obtained from patients with
advanced atherosclerosis (both coronary and carotid) [8–11]. In
two independent studies, levels of lysoPC, a product of Lp-PLA2
activity, were found in significantly greater concentrations in
symptomatic than in asymptomatic carotid plaques and were
highly and significantly correlated with Lp-PLA2 levels [10–11].
Lp-PLA2 concentrations in symptomatic lesions were greatest
within the necrotic core and in the shoulder regions, which were
also regions known to have high concentrations of macrophages
and oxidized low-density lipoprotein [8,25].
In the current carotid endarterectomy study, no statistically
significant differences were observed between treatment groups in
plaque lysoPC levels (total or subfractions). Furthermore, no
statistically significant differences were observed between treat-
ment groups in serum biomarkers or in other plaque biomarkers,
including Lp-PLA2 mRNA. However, a short treatment regimen
(2 to 4 weeks) was utilized, which could account for these results.
In a separate dose-ranging trial [21] involving a longer duration of
treatment (12 weeks) and including a 160-mg dose of the enteric-
coated formulation of darapladib that provides comparable
exposure to the 80-mg dose of the non–enteric-coated formulation
used in the present study, a significant reduction was observed in
plasma IL-6 compared with placebo (P,0.028). No statistically
significant changes were observed for other CV risk markers.
Although histopathologic assessment of carotid plaque compo-
sition was not performed on excised lesions, the excised plaques
contained a surprisingly large amount of lysoPC (,3 mmol/g of
tissue). If lesion Lp-PLA2 was the primary source for the majority
of this lysoPC, then the greatest benefit of darapladib would be
Table 2. Summary of adverse experiences during treatment (1464 days) in the carotid endarterectomy study.
Placebo Darapladib 40 mg Darapladib 80 mg
(N=34) (N=34) (N=34)
Deaths, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Patients with any adverse event, n (%) 5 (14.7) 11 (32.4) 11 (32.4)
Patients with treatment-related adverse event, n (%) 0 (0.0) 3 (8.8) 2 (5.9)
Patients discontinuing treatment from a treatment-related
adverse event, n (%)
0 (0.0) 0 (0.0) 0 (0.0)
Patients with serious adverse event, n (%) 0 (0.0) 3 (8.8) 2 (5.9)
Common adverse events, n (%)
Dysgeusia 0 (0.0) 3 (8.8) 3 (8.8)
Fecal abnormality 0 (0.0) 4 (11.8) 2 (5.9)
Fatigue 0 (0.0) 1 (2.9) 2 (5.9)
Headache 2 (5.9) 1 (2.9) 0 (0.0)
Nausea 2 (5.9) 0 (0.0) 0 (0.0)
doi:10.1371/journal.pone.0089034.t002
Figure 5. The influence of darapladib treatment (14±4 days) on plaque (A) caspase-3 activity and (B) caspase-8 activity (mean ±
SEM). P values represent comparisons of darapladib 80 mg with placebo. AU, activity units.
doi:10.1371/journal.pone.0089034.g005
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dependent upon the clearance of this intra-lesional pool of
proinflammatory lipid, which could conceivably take several
weeks or even months of treatment to normalize. The reduction,
however, in two markers of apoptosis, caspase-3 and caspase-8
activity, versus placebo and a correlation between Lp-PLA2
inhibition and caspase activity are intriguing findings. Apoptosis is
increased in atherosclerotic lesions, with most cell death occurring
within the macrophage-rich necrotic core of the plaque [26].
Although these measures of apoptosis were from a post-hoc
analysis of stored tissue samples and would need to be reproduced
in a prospective study, the reduction in these apoptosis markers
would appear to be in agreement with results from two other
studies involving the longer use of darapladib. In the Integrated
Biomarker and Imaging Study (IBIS-2) [15], treatment with
darapladib for 12 months halted necrotic core expansion as
assessed by serial intravascular ultrasound examinations. These
findings are consistent with observations from a second study
involving a preclinical model of atherosclerosis (diabetic, hyper-
cholesterolemic porcine model), in which treatment with darapla-
dib inhibited the progression to complex coronary artery lesions
[13]. Whether these changes will translate into differences in
clinical outcomes awaits the results of the previously mentioned
ongoing phase III trials, STABILITY and SOLID-TIMI 52.
Limitations
This study does not address the potential clinical effects of Lp-
PLA2 inhibition with respect to CV events. Given the relatively
small sample sizes and the short duration of treatment (2 to 4
weeks), these results should be viewed as preliminary and
hypothesis-generating. Nevertheless, demonstrating a pharmaco-
dynamic effect within human atherosclerotic lesions provides a
rationale, along with results from other trials, for studying the
effects of treatment with darapladib in larger trials of longer
duration.
Conclusions
Although it is widely accepted that intensifying treatment for
primary and secondary prevention of CV disease improves
outcomes, CV event rates for high-risk individuals remain
unacceptably high. Treatments that modulate processes involved
in plaque destabilization and atherothrombosis may offer addi-
tional benefit for reducing CV events. The findings from this study
suggest that darapladib does indeed distribute into advanced
human atherosclerotic lesions to produce a dose-dependent
reduction in Lp-PLA2 activity that is comparable in magnitude
to what has been observed in plasma. Results from ongoing event-
driven trials are now needed to explore the effects of Lp-PLA2
inhibition on CV outcomes.
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